Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1998-6-18
|
pubmed:abstractText |
The objective of this study was to evaluate the effects of itraconazole as a first choice drug in the treatment of pulmonary aspergillosis in heart transplant recipients. Heart transplant recipients suffering from invasive pulmonary aspergillosis were included in this study. Group 1 included 4 patients treated with i.v. itraconazole (Janssen Pharmaceutica) 400 mg daily, as a first choice drug for 28 d. Itraconazole was discontinued and amphotericin-B was started before the 28th day if clinical or radiographic worsening was observed. Group 2 included 3 patients treated with amphotericin-B as a first choice drug. Itraconazole was discontinued in all patients of Group 1 after 12-26 d of treatment because of radiographic worsening (n = 3) or combined clinical and radiographic worsening (n = 1). Subsequent treatment with amphotericin-B resulted in improvement of all patients. On a 5-yr follow-up period no relapse of aspergillosis was observed in 3 of them. The fourth patient expired from cerebral hemorrhage. The 3 patients of Group 2 treated with amphotericin-B showed a gradual improvement, and all were doing well on a 2-yr follow-up. In conclusion, in our study population consisted of heart transplant recipients amphotericin-B was superior to itraconazole in the treatment of invasive pulmonary aspergillosis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0902-0063
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
30-4
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:9541420-Adult,
pubmed-meshheading:9541420-Amphotericin B,
pubmed-meshheading:9541420-Antifungal Agents,
pubmed-meshheading:9541420-Aspergillosis,
pubmed-meshheading:9541420-Aspergillus fumigatus,
pubmed-meshheading:9541420-Heart Transplantation,
pubmed-meshheading:9541420-Humans,
pubmed-meshheading:9541420-Itraconazole,
pubmed-meshheading:9541420-Lung Diseases, Fungal,
pubmed-meshheading:9541420-Microbial Sensitivity Tests,
pubmed-meshheading:9541420-Middle Aged,
pubmed-meshheading:9541420-Opportunistic Infections
|
pubmed:year |
1998
|
pubmed:articleTitle |
Itraconazole for the treatment of pulmonary aspergillosis in heart transplant recipients.
|
pubmed:affiliation |
University of Athens, School of Medicine, Department of Clinical Therapeutics, Alexandra Hospital, Greece.
|
pubmed:publicationType |
Journal Article
|